International Clinical Trial: Tildrakizumab followed by ixekizumab for moderate-to-severe plaque psoriasis: efficacy and safety

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128669) titled 'Tildrakizumab followed by ixekizumab for moderate-to-severe plaque psoriasis: efficacy and safety' on July 23.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Condition: Psoriasis

Intervention: Telricizumab monotherapy group:Telricizumab (100mg) was subcutaneously injected at weeks 0, 4, 16, 28, 40, and 52.

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-08-06

Target Sample Size: Telricizumab monotherapy group:32;Telricizumab followed by cilizumab treatment group:32; ...